Hemophilia A

Advate, a clotting therapy, gets FDA approval

Published in Blood Weekly, August 28th, 2003

Baxter Healthcare Corp. announced that the U.S. Food and Drug Administration (FDA) has approved Advate (antihemophilic factor (recombinant), plasma/albumin-free method) rAHF-PFM for the prevention and control of bleeding episodes in people with hemophilia A.

According to Baxter, Advate is the first and only factor VIII made without any added human or animal plasma proteins and albumin in the cell culture process, purification, and final formulation, thereby eliminating the risk of infections caused by viruses that may be carried in these proteins.

Developed by Baxter, Advate is a genetically engineered, or recombinant, full-length clotting factor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-08-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry